Brentuximab vedotin is approved for the treatment of many tumors such as Hodgkin lymphoma (HL), CD30+ PTCL, and CD30+ CTCL. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.